Identification of the molecular lesion in Caenorhabditis elegans mutants isolated through forward genetic screens usually involves time-consuming genetic mapping. We used Illumina deep sequencing technology to sequence a complete, mutant C. elegans genome and thus pinpointed a single-nucleotide mutation in the genome that affects a neuronal cell fate decision. This constitutes a proof-of-principle for using wholegenome sequencing to analyze C. elegans mutants.
C. elegans is used extensively to identify genes involved in various aspects of animal development, behavior and physiology 1 (http:// www.wormbook.org/). The traditional forward genetic approach involves random mutagenesis and subsequent isolation of mutants defective in a given process 1 . The ensuing characterization of the molecular lesion in a mutant strain is a painstaking process that involves mapping with genetic and/or single-nucleotide polymorphism (SNP) markers. The relative gene density in C. elegans and limited recombinant frequencies can make traditional mapping a very time-consuming process. This issue becomes even more apparent when the scoring of the mutant phenotype is cumbersome and recombinants are therefore tedious to identify. Another problem with traditional mapping approaches is that genetic-background effects on a given phenotype prohibit the use of many genetic markers and mapping strains.
We considered whole-genome sequencing as an approach to identify the molecular lesion in a specific ethyl methanesulfonate (EMS)-induced mutant C. elegans strain. We had previously described a genetic locus, lsy-12, in which a neuronal fate decision is aberrantly executed 2 . Instead of generating two left/right asymmetric, distinct chemosensory neurons, ASEL and ASER, lsy-12 mutants generate two ASER neurons 2 . To determine the molecular identity of lsy-12, we undertook a single mapping cross of the recessive lsy-12 allele ot177 (lsy-12(ot177)) with a Hawaiian mapping strain 3 , analyzed 200 F 2 progeny for SNPs by PCR and thereby mapped lsy-12(ot177) to a 4-Mb interval on chromosome V. This interval represents 4% of the genome and contains 1,142 predicted genes (5% of total genes).
We prepared genomic DNA from lsy-12(ot177) worms and sequenced the DNA using paired-end Illumina (formerly Solexa) sequencing technology 4 . We generated 4.35 Gb of paired 35-mer sequence reads in a 1-week sequencing run. Then we mapped the sequence data to the wild-type N2 reference genome using ELAND (efficient large-scale alignment of nucleotide databases) and the Maq alignment tools (Supplementary Methods online) ; 3.1 Gb of reads were mapped exactly onto the genome with an average coverage of ~28×. To label differences between our sequence data and the N2 reference genome as 'variants', we filtered for those reads that mapped uniquely with high-quality scores on both strands and were read at least ten times, thus eliminating the vast majority of ambiguous calls (Supplementary Methods). The filtering left 80 variants between lsy-12(ot177) genomic DNA and the published N2 wild-type reference genome in the 4-Mb interval, into which lsy-12(ot177) mapped. We ranked these 80 variants according to standard quality scores (Supplementary Table 1 online) . Fifty-four of the 80 variants were single-nucleotide variants and 26 were small, mainly 1-nt insertions-deletions (indels; Fig. 1 To determine whether the detected variations were (i) sequencing or mapping errors in the Illumina Genome Analyzer pipeline, (ii) sequence variations in the original transgenic strain mutagenized, a strain containing the transgene otIs114 (ref. 5) or (iii) true mutagenesis-induced mutations, we PCR-amplified ~300-bp fragments that contained each of the 80 variants from both the starting strain used for mutagenesis (strain containing the transgene otIs114), and from the mutant strain (lsy-12(ot177)), which also contains the unlinked otIs114 transgene. Each of these strains had been outcrossed against N2 wild-type multiple times. Resequencing of the amplicons derived from the lsy-12(ot177) mutant strain by the traditional Sanger method confirmed the presence of all of the 26 indels. Notably, all of the indels were already present in the transgenic starting strain containing the transgene otIs114. We then Sanger-sequenced the genomic regions containing these indels in our available N2 wild-type isolate and found each of the indels to be present in N2 as well. We therefore unintentionally uncovered a large amount of sequence variation between the N2 reference genome and the N2 wild-type strain were present in both the starting strain containing the transgene otIs114 and also in our N2 wild-type strain, again underscoring the sequence differences between the reference genome and our wild-type strain ( Fig. 1 and Table 1) .
We confirmed 15 out of the 21 exonic variants, and specifically 11 of the 16 exonic variants that altered an amino acid, by Sanger resequencing (Supplementary Table  1a ). The remaining erroneous variants again had lower quality scores and in each case, we observed more wild-type than variant reads ( Fig. 1 and Supplementary Table 1a) . Of the 11 confirmed exonic variants that alter an amino acid, 7 were already present in the starting strain containing the transgene otIs114 and most of these again were present in our N2 wild-type isolate (Fig. 1) . This left 4 amino acid-changing variants between the lsy-12(ot177) mutant and the N2 wild-type genome in the mapped 4-Mb interval (Fig. 2) . In sum, we discounted the majority of initial variations in the mapped 4-Mb interval (80 variants) as they did not affect protein-coding regions (64 of original 80 variants, 80%) and/or were sequencing errors and/or are variations between strain backgrounds, leaving only a total of four exonic variants that we predicted to alter a protein product (Fig. 1 and Table 1) .
One of these four exonic variants is a nonsense mutation in the predicted R07B5.9 gene, the sole nonsense mutation in the entire dataset. We sequenced this predicted gene in the other five available strains that harbor mutant alleles of lsy-12, as determined by complementation testing and mapping (Supplementary Methods and Supplementary Table 3 online). We found that each one of them harbors a mutation in R07B5.9 (Fig. 2) . None of the lsy-12 strains displayed variations in the other three candidate genes revealed by genome sequencing. Moreover, the lsy-12 mutant phenotype was rescued by injecting a ~39 kb genomic interval that contains R07B5.9 but no other candidate gene suggested by the wholegenome analysis (Fig. 2 and Supplementary Table 3) . Lastly, we performed RNA interference (RNAi) of all four genes with exonic variants and found that only RNAi of R07B5.9 phenocopies the lsy-12 mutant phenotype (Supplementary Table 3) . We concluded that distributed by the Caenorhabditis Genetics Center at the University of Minnesota, which could be due to genetic drift or to errors in sequencing the reference genome. These findings are consistent with a previous study 6 .
We confirmed 17 of the 33 non-exonic variants by Sangersequencing of lsy-12(ot177) (Fig. 1) . The remaining 16 unconfirmed 'variants' (10 were apparent sequencing errors and 6 were clustered within a single intron that we could not reliably identify in the genome) were supported by less variant reads than wild-type reads, thereby suggesting another rule by which to filter variants (Supplementary figure 1 | Variants found in whole-genome sequence analysis. ot177 is shorthand for lsy-12(ot177). The asterisk denotes 6 variants clustered within 100 bp of a single intron (supplementary Table 1a ), which upon amplification and Sanger-sequencing we found to map at least in part onto a different chromosome. True variations between starting strain (strain containing the transgene otIs114) and mutant strain (lsy-12(ot177); otIs114) over total variations 18.9% (9 + 1 + 4) / (80 -6 a )
Variations due to differences between available N2 strain and reference genome over total variations 56.8% (26 + 8 + 3 + 5) / (80 -6 a ) a Six variants clustered within 100 bp of a single intron (supplementary Table 1a ), which upon amplification and Sanger sequencing we found to map at least in part onto a different chromosome. We subtracted these six variants in the summary calculations as their source was not clear.
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example, behavioral mutants), mutants for which the phenotype is subject to modification by the genetic background of mapping strains and mutants that require specific genetic backgrounds (that is, modifier mutants), can now be more easily identified by wholegenome sequencing.
lsy-12 is R07B5.9. Whole-genome sequencing has therefore revealed the identity of a previously unknown mutant gene. The ability to perform additional experiments to distinguish the true phenotypecausing mutation from the set of sequence variants identified by whole-genome sequencing will dictate the amount of mapping one needs to perform before using whole-genome sequencing. From our identification of four protein-changing variants in a 4-Mb interval, we extrapolate that an entire chromosome, such as chromosome V (20.9 Mb), may only contain ~20 proteinchanging candidate variants. The availability of multiple alleles is the easiest way to sift through these candidates, as it is fast and simple to manually Sanger-sequence many candidate genes in the allelic strains. RNAi and transformation rescue represent other powerful tools to test whether sequence variants are responsible for the mutant phenotype. We conclude that minimal mapping to as little as a chromosome and perhaps even less is required before using a whole-genome sequencing strategy.
To facilitate the design of future studies, we statistically analyzed the sequence data and found that the number of reads at a particular location (that is, the coverage), did not follow traditional formulae 7 but could be approximated as a gamma-distributed random variable (see Supplementary Methods and Supplementary Table 4 online). Under the assumption of our observed 0.6% error rate, this observation predicts that 8× coverage would yield ~150 variants in a 4-Mb interval, supported by at least four variant reads (see Supplementary Methods for details on these predictions and their detection power). Given that, in our case, only 4 in 80 variants in a 4-Mb interval were non-silent variants within a coding region (Fig. 1) , this would translate into only ~8 variants requiring validation. We therefore recommend aiming for eightfold coverage, which should be reached with ~0.8 Gb of aligned sequence, produced by two lanes in a Genome Analyzer flow cell.
The application of whole-genome sequencing offers many unique advantages. The sequence run only takes a few days and costs are in the few-thousand dollar range, which compare favorably to the personnel and reagent costs of a traditional multi-year gene cloning project. The implications of the substantial time savings with this approach go beyond mere cost considerations. The approach should motivate large-scale genetic screens, followed by the rapid sequencing of many mutants retrieved from such screens. This will not only lead to a more comprehensive genetic understanding of a given biological process but will offer the practical advantage of being able to sift through a collection of mutants and to focus on those genes whose molecular identity bear the most interest to the investigator. Moreover, mutants for which the phenotype is tedious to score (for 
